Tenax Therapeutics (NASDAQ:TENX) Stock Breaks Above Fifty Day Moving Average – Time to Sell?

Tenax Therapeutics, Inc. (NASDAQ:TENX)’s stock price crossed above its 50-day moving average during trading on Wednesday. The stock has a 50-day moving average of $1.84 and traded as high as $1.89. Tenax Therapeutics shares last traded at $1.88, with a volume of 1,653,196 shares trading hands.

Tenax Therapeutics News Roundup

Here are the key news stories impacting Tenax Therapeutics this week:

• Negative Sentiment: The lawsuit covers investors who purchased Tenax securities from November 13, 2023, through August 7, 2026. The case was filed in federal court and alleges potential violations of U.S. securities laws; the allegations have not been proven. Pomerantz class-action announcement
• Negative Sentiment: The legal claims appear linked to company disclosures concerning TNX-103 and the Phase 3 LEVEL study, including alleged assurances that the trial was enriched with patients most likely to respond. One law firm is also investigating potential securities fraud related to disclosures made on August 10, 2026. Frank R. Cruz investigation
• Negative Sentiment: A series of notices from Bronstein Gewirtz & Grossman, Berger Montague, Kaplan Fox, Faruqi & Faruqi, Rosen, and other firms is increasing visibility around the litigation and may reinforce investor concerns about potential financial, disclosure, and reputational risks. These announcements largely promote the same filed action rather than documenting separate new lawsuits. Bronstein Gewirtz & Grossman announcement
• Neutral Sentiment: Investors who seek to become lead plaintiff must generally apply by December 28, 2026. The deadline itself does not establish liability or guarantee recovery, but it signals that the legal process is moving forward. Berger Montague class-action notice

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Cantor Fitzgerald restated an “overweight” rating on shares of Tenax Therapeutics in a research report on Thursday, September 10th. Guggenheim downgraded shares of Tenax Therapeutics from a “buy” rating to a “neutral” rating in a report on Monday, August 31st. Roth Capital set a $5.00 target price on shares of Tenax Therapeutics in a research report on Monday, August 10th. Evercore cut shares of Tenax Therapeutics from an “outperform” rating to an “in-line” rating and set a $5.00 target price for the company. in a research note on Tuesday, August 11th. Finally, Leerink Partners set a $4.00 target price on shares of Tenax Therapeutics in a research note on Tuesday, August 11th. One analyst has rated the stock with a Strong Buy rating, three have assigned a Buy rating, five have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $14.00.

Tenax Therapeutics Price Performance

The business’s 50 day simple moving average is $1.84 and its 200 day simple moving average is $10.10. The company has a market capitalization of $66.98 million, a PE ratio of -1.21 and a beta of 0.92.

Tenax Therapeutics (NASDAQ:TENX) last posted its quarterly earnings results on Friday, July 31st. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, beating the consensus estimate of ($0.38) by $0.03. As a group, analysts anticipate that Tenax Therapeutics, Inc. will post -1.38 EPS for the current year.

Insider Buying and Selling

In other Tenax Therapeutics news, major shareholder Adar1 Capital Management, Llc acquired 900,000 shares of the stock in a transaction that occurred on Thursday, September 3rd. The stock was bought at an average cost of $1.78 per share, for a total transaction of $1,602,000.00. Following the completion of the transaction, the insider owned 6,524,151 shares of the company’s stock, valued at approximately $11,612,988.78. The trade was a 16.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Insiders purchased 3,682,899 shares of company stock valued at $6,388,279 in the last 90 days. Corporate insiders own 10.81% of the company’s stock.

Institutional Investors Weigh In On Tenax Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. State of Alaska Department of Revenue acquired a new stake in shares of Tenax Therapeutics during the 3rd quarter worth about $94,000. Bank of America Corp DE raised its holdings in Tenax Therapeutics by 391.2% in the 1st quarter. Bank of America Corp DE now owns 18,569 shares of the specialty pharmaceutical company’s stock valued at $297,000 after buying an additional 14,789 shares during the period. Squarepoint Ops LLC acquired a new position in Tenax Therapeutics in the second quarter valued at about $485,000. The Manufacturers Life Insurance Company acquired a new position in Tenax Therapeutics in the first quarter valued at about $501,000. Finally, Dimensional Fund Advisors LP acquired a new position in Tenax Therapeutics in the first quarter valued at about $1,001,000. Institutional investors and hedge funds own 1.67% of the company’s stock.

About Tenax Therapeutics

Tenax Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on developing therapies for cardiovascular and pulmonary diseases. The company’s research programs are aimed at addressing conditions with significant unmet medical needs, including pulmonary hypertension associated with heart failure with preserved ejection fraction (PH-HFpEF).

Tenax’s lead product candidate is TNX-103, an oral formulation of levosimendan. Levosimendan is a calcium sensitizer and potassium-channel activator that has been approved for certain heart-failure indications outside the United States.